New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
07:28 EDTGILDMacroGenics and Gilead enter strategic alliance to develop DART products
MacroGenics announced it has entered into a license agreement with Gilead for the development and commercialization of Dual-Affinity Re-Targeting products directed at up to four undisclosed targets. MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. Under the terms of the agreement, MacroGenics could receive a total of up to $30M in license fee payments, and up to an additional $85M in pre- clinical milestones across the four DART programs. Gilead has exclusive worldwide rights for three of the programs. For one program, MacroGenics retains development and commercialization rights outside of North America, Europe, Australia and New Zealand, which encompasses multiple major markets including Japan, China, Korea, Brazil, Russia and others. Gilead will fully fund MacroGenics' research activities with respect to the four programs. MacroGenics could also receive up to approximately $1B in clinical, regulatory and commercialization milestone payments if all four programs achieve the requisite milestones.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
14:33 EDTGILDAbbVie comments affirm 25/75 HCV market split with Gilead, says Wells Fargo
Subscribe for More Information
14:26 EDTGILDGilead Q4 HCV sales should meet consensus, says BofA/Merrill
Subscribe for More Information
07:57 EDTGILDGilead February weekly volatility elevated into Q4 and outlook
Gilead February weekly call option implied volatility is at 79, February is at 35, March is at 31, April is at 30; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on February 3.
January 29, 2015
09:37 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL FB KO NFLX PFMT GILD YHOO TSLA MCD
08:44 EDTGILDUnitedHealth selects Gilead's Harvoni for hepatitis C coverage, Reuters says
Subscribe for More Information
January 28, 2015
09:35 EDTGILDActive equity options trading
Subscribe for More Information
January 27, 2015
16:00 EDTGILDOptions Update; January 27, 2015
iPath S&P 500 VIX Short-Term Futures up 1.40 to 32.01. Option volume leaders: AAPL TSLA TWTR AMZN FB MSFT X RIG YHOO C GILD according to Track Data.
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL MSFT TWTR TSLA GILD NFLX C AA HPQ X
08:53 EDTGILDGilead February weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 26, 2015
16:01 EDTGILDOptions Update; January 26, 2015
iPath S&P 500 VIX Short-Term Futures down 1.47 to 30.63. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX X MSFT BP GILD according to Track Data.
13:01 EDTGILDGilead, EnvisionRx sign exclusive agreement for Sovaldi, Harvoni availability
Subscribe for More Information
11:00 EDTGILDMylan expands Hepatitis C licensing agreement with Gilead
Mylan (MYL) announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences (GILD) to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available. This agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries. Mylan also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.
09:49 EDTGILDActive equity options trading
Subscribe for More Information
05:11 EDTGILDGilead expands hepatitis C generic licensing agreements
Subscribe for More Information
January 23, 2015
09:35 EDTGILDGilead mentioned cautiously at Cleveland Research
Subscribe for More Information
January 20, 2015
16:00 EDTGILDOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
09:38 EDTGILDActive equity options trading
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use